XBIT News and Press, XBiotech Inc. From 02/02/22

XBiotech (XBIT -2.6%) will manufacture Johnson & Johnson (JNJ +0.2%) division Janssen Research & Development products, including the monoclonal antibody Xilonix (bermekimab). Xilonix was sold to Janssen by XBiotech in December 2019. That out-licensing deal, which allows Janssen to dev...

AUSTIN, Texas, Feb. 02, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it executed Manufacturing Agreement with Janssen Research & Development, LLC to manufacture clinical product, including Bermekimab, a True Human monoclonal antibody sold to Janssen by XBio...

The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...

AUSTIN, Texas, Dec. 13, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to commence clinical development of Natrunix, the Company’s novel True Human™ antibody candidate therapy f...

AUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today its plan to commence a randomized, placebo-controlled clinical study to test its new True Human™ antibody therapy for reducing brain injury after stroke. The study will be conducted across t...

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced that Benjamin Musher M.D., will chair XBiotech’s clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix™, to ...

AUSTIN, Texas, Aug. 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the addition of Mark Ziats, M.D. Ph.D. as Medical Director. Dr. Ziats will be involved in developing and managing a diverse clinical portfolio for the Company’...

AUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Common Stock issued and outst...

Mikhail Leonov/iStock via Getty Images Funding in the biotech space led to a couple of major advances in Wednesday's pre-market. OncoSec (ONCS) rallied on news of a collaboration deal with Merck (MRK). Daré Bioscience (DARE) also gained ground before the bell, thanks to a grant from the ...

AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.’s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-t...